WEBULL
WebtradeDownload

Can Johnson & Johnson (JNJ) Justify A Discount To Cash Flow?

Simply Wall St · 1d ago

Johnson & Johnson has delivered a powerful run over the past few years, and with the stock now near US$269, investors are increasingly asking whether that price is fully backed by the cash the business can generate. With fresh clinical data and portfolio moves reshaping expectations for its pharmaceuticals and medical technology operations, the key issue is how those developments feed into the durability and size of Johnson & Johnson's future cash flows.

  • Over the past 5 years the stock has returned 88.7%, which reflects a high degree of confidence in Johnson & Johnson's ability to keep turning its pipeline and product portfolio into cash generation.
  • New trial results for treatments such as TECVAYLI plus DARZALEX FASPRO and RYBREVANT based regimens may support expectations for longer treatment durations and extended product lifecycles, which can influence both the level and timing of cash flows feeding into any intrinsic value estimate.
  • If you'd rather focus on earnings, this one's for you. See why Johnson & Johnson's 30.8x P/E tells a different valuation story.

The issue now is whether Johnson & Johnson's current share price can be explained by what a Discounted Cash Flow (DCF) view of its future cash streams suggests the stock is worth.

To see how Johnson & Johnson's cash flow story compares with other potential opportunities in healthcare and beyond, review it alongside companies in the solid balance sheet and fundamentals stocks screener (23 results).

Does Johnson & Johnson Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here uses Johnson & Johnson's expected future free cash generation to estimate what the equity could be worth today.

On the raw cash side, the group has produced roughly $21.7b of free cash flow over the last twelve months, and the DCF framework assumes those flows keep growing rather than shrinking. Forecasts used in the model point to higher annual free cash flow by 2030, with growth stepping down into a steadier second stage that fits a large, mature healthcare business with an established product base.

Because the DCF projections put Johnson & Johnson's estimated intrinsic value meaningfully above the current share price of $269.17, the model suggests the market is not fully reflecting those projected cash streams. New Phase 3 data for TECVAYLI plus DARZALEX FASPRO, which points to extended disease control and survival in multiple myeloma, helps explain why analysts are comfortable underwriting ongoing cash generation in the forecast period. Find out what Johnson & Johnson could be worth using our Discounted Cash Flow (DCF) estimate.

The Johnson & Johnson Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the DCF puzzle leaves off by spelling out which assumptions about Johnson & Johnson's growth, margins and earnings would need to hold for the shares to be worth materially more or less than today. These narratives sit on the stock's Community page.

Each narrative ties a specific fair value view to a clear storyline about Johnson & Johnson's potential catalysts and key risks so you can track over time which version of events appears to be unfolding.

Community views on Johnson & Johnson split between those who see more upside in the pipeline and MedTech build out and those who think the current price already reflects that strength.

Bull case: roughly fairly valued

"The company's substantial investment of over $55 billion into manufacturing, R&D, and technology in the U.S. over the next four years is projected to expand capacity for advanced medicines and devices..."

Discover why this Narrative puts Johnson & Johnson at roughly fairly valued.

Bear case: 9% overvalued

"At approximately 22× earnings, JNJ trades near sector averages but commands a modest premium for stability, balance sheet strength, and consistent free cash flow..."

Explore why this Narrative puts Johnson & Johnson at 9% overvalued.

The unanswered Johnson & Johnson question, who is steering it and on what terms?

Valuation work only goes so far if you do not also examine who is making the key calls at Johnson & Johnson and how their rewards line up with long term outcomes. See who runs Johnson & Johnson and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.